Loading...

Avinger, Inc.

AVGRNASDAQ
Healthcare
Medical - Instruments & Supplies
$0.47
$-0.12(-20.74%)

Avinger, Inc. (AVGR) Stock Overview

Explore Avinger, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 60.6/100

Key Financials

Market Cap1.5M
P/E Ratio-0.06
EPS (TTM)$-8.76
ROE-54.25%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 Months$0.00
1 Year Target$0.16

AVGR Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Avinger, Inc. (AVGR) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.16.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.06 and a market capitalization of 1.5M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for AVGRStats details for AVGR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for AVGRAnalyst Recommendations details for AVGR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.

CEO

Nabeel P. Subainati CPA

Employees

68

Headquarters

400 Chesapeake Drive, Redwood City, CA

Founded

2015

Frequently Asked Questions

;